EYEPOINT PHARMACEUTICALS INC (EYPT)
US30233G2093 - Common Stock
Overall EYPT gets a fundamental rating of 4 out of 10. We evaluated EYPT against 192 industry peers in the Pharmaceuticals industry. While EYPT has a great health rating, there are worries on its profitability. EYPT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year EYPT has reported negative net income.
EYPT had a negative operating cash flow in the past year.
In the past 5 years EYPT always reported negative net income.
EYPT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
EYPT has a Return On Assets (-34.42%) which is comparable to the rest of the industry.
With a Return On Equity value of -47.35%, EYPT perfoms like the industry average, outperforming 58.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.42% | ||
| ROE | -47.35% | ||
| ROIC | N/A |
ROA(3y)-32.93%
ROA(5y)-45.22%
ROE(3y)-54.78%
ROE(5y)-218.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of EYPT (91.48%) is better than 95.11% of its industry peers.
In the last couple of years the Gross Margin of EYPT has grown nicely.
The Profit Margin and Operating Margin are not available for EYPT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.48% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.68%
GM growth 5YN/A
2. Health
2.1 Basic Checks
EYPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EYPT has been increased compared to 1 year ago.
EYPT has more shares outstanding than it did 5 years ago.
EYPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -0.02, we must say that EYPT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of EYPT (-0.02) is comparable to the rest of the industry.
EYPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.02 |
ROIC/WACCN/A
WACC10.64%
2.3 Liquidity
A Current Ratio of 5.50 indicates that EYPT has no problem at all paying its short term obligations.
EYPT has a better Current ratio (5.50) than 68.48% of its industry peers.
A Quick Ratio of 5.45 indicates that EYPT has no problem at all paying its short term obligations.
EYPT has a better Quick ratio (5.45) than 70.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.5 | ||
| Quick Ratio | 5.45 |
3. Growth
3.1 Past
EYPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.81%, which is quite impressive.
The Revenue has been growing slightly by 7.51% in the past year.
The Revenue has been growing by 73.11% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)24.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.64%
Revenue 1Y (TTM)7.51%
Revenue growth 3Y10.14%
Revenue growth 5Y73.11%
Sales Q2Q%-30.77%
3.2 Future
The Earnings Per Share is expected to grow by 19.35% on average over the next years. This is quite good.
The Revenue is expected to grow by 45.97% on average over the next years. This is a very strong growth
EPS Next Y-26.2%
EPS Next 2Y-21.97%
EPS Next 3Y-18.16%
EPS Next 5Y19.35%
Revenue Next Year5.11%
Revenue Next 2Y-38.44%
Revenue Next 3Y-40.26%
Revenue Next 5Y45.97%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
EYPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EYPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EYPT's earnings are expected to decrease with -18.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.97%
EPS Next 3Y-18.16%
5. Dividend
5.1 Amount
No dividends for EYPT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EYEPOINT PHARMACEUTICALS INC
NASDAQ:EYPT (1/6/2025, 4:38:55 PM)
After market: 8.68 0 (0%)8.68
+0.42 (+5.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners109.28%
Inst Owner Change0%
Ins Owners1.14%
Ins Owner Change0.1%
Market Cap591.11M
Analysts84.44
Price Target33.66 (287.79%)
Short Float %14.5%
Short Ratio9.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.71%
Min EPS beat(2)-8.31%
Max EPS beat(2)4.9%
EPS beat(4)2
Avg EPS beat(4)0.1%
Min EPS beat(4)-29.62%
Max EPS beat(4)33.44%
EPS beat(8)4
Avg EPS beat(8)-28.67%
EPS beat(12)7
Avg EPS beat(12)-16.57%
EPS beat(16)8
Avg EPS beat(16)-43.19%
Revenue beat(2)1
Avg Revenue beat(2)-0.37%
Min Revenue beat(2)-3.15%
Max Revenue beat(2)2.41%
Revenue beat(4)3
Avg Revenue beat(4)17.11%
Min Revenue beat(4)-3.15%
Max Revenue beat(4)54.46%
Revenue beat(8)5
Avg Revenue beat(8)10.54%
Revenue beat(12)7
Avg Revenue beat(12)7.37%
Revenue beat(16)7
Avg Revenue beat(16)0.01%
PT rev (1m)0%
PT rev (3m)-11.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.94%
EPS NY rev (1m)0%
EPS NY rev (3m)4.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)18.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12.93 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.7 | ||
| P/tB | 2.7 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2
EYN/A
EPS(NY)-2.72
Fwd EYN/A
FCF(TTM)-1.73
FCFYN/A
OCF(TTM)-1.67
OCFYN/A
SpS0.67
BVpS3.21
TBVpS3.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.42% | ||
| ROE | -47.35% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.48% | ||
| FCFM | N/A |
ROA(3y)-32.93%
ROA(5y)-45.22%
ROE(3y)-54.78%
ROE(5y)-218.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.68%
GM growth 5YN/A
F-Score4
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 383.4% | ||
| Cap/Sales | 9.96% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.5 | ||
| Quick Ratio | 5.45 | ||
| Altman-Z | -0.02 |
F-Score4
WACC10.64%
ROIC/WACCN/A
Cap/Depr(3y)281.39%
Cap/Depr(5y)173.17%
Cap/Sales(3y)4.4%
Cap/Sales(5y)3.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.64%
EPS Next Y-26.2%
EPS Next 2Y-21.97%
EPS Next 3Y-18.16%
EPS Next 5Y19.35%
Revenue 1Y (TTM)7.51%
Revenue growth 3Y10.14%
Revenue growth 5Y73.11%
Sales Q2Q%-30.77%
Revenue Next Year5.11%
Revenue Next 2Y-38.44%
Revenue Next 3Y-40.26%
Revenue Next 5Y45.97%
EBIT growth 1Y-43.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year318.02%
EBIT Next 3Y71.73%
EBIT Next 5YN/A
FCF growth 1Y-67.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-64.25%
OCF growth 3YN/A
OCF growth 5YN/A